NPS Pharmaceuticals, Inc.
) is scheduled to report its fourth-quarter 2013 results after
the closing bell on Feb 18. Last quarter, NPS Pharma had
delivered an earnings surprise of +50.00%. Let's see how things
are shaping up for this announcement.
Factors at Play
NPS Pharma has delivered positive earnings surprises in three of
the last four quarters with an average beat of 9.88%.
Although sales of Gattex, the only approved product at NPS Pharma
(launched in Feb 2013 in the U.S.), will boost revenues, higher
operating costs will partially offset the positive impact of
Gattex sales. NPS Pharma is actively investing in its pipeline as
well as making efforts to market Gattex effectively. Increased
costs will hurt the bottom line.
Our proven model does not conclusively show that NPS Pharma is
likely to beat earnings this quarter. That is because a stock
needs to have both a positive
(Expected Surprise Prediction) and a Zacks Rank of #1, 2 or 3 for
this to happen. That is not the case here as you will see below.
The Earnings ESP for NPS Pharma is 0.00% since the Most Accurate
Estimate is 2 cents, in line with the Zacks Consensus Estimate.
NPS Pharma's Zacks Rank #3 (Hold) has little effect on the
predictive power of ESP because the Zacks Rank #3 when combined
with a 0.00% ESP makes surprise prediction difficult.
Other Stocks to Consider
Here are some companies you may want to consider as our model
shows that they have the right combination of elements, i.e., a
positive Zacks Earnings ESP and a Zacks Rank #1, 2 or 3.
) has an Earnings ESP of +0.33% and holds a Zacks Rank #2 (Buy).
Actavis will be reporting fourth quarter earnings on Feb 20.
) has an Earnings ESP of +11.11% and holds a Zacks Rank #1
(Strong Buy). NuVasive will be reporting fourth-quarter earnings
on Mar 3.
) has an Earnings ESP of +36.36% and holds a Zacks Rank #2 (Buy).
NuVasive will be reporting fourth-quarter earnings on Feb 27.
ACTAVIS PLC (ACT): Free Stock Analysis Report
MEDIVATION INC (MDVN): Free Stock Analysis
NPS PHARMA INC (NPSP): Free Stock Analysis
NUVASIVE INC (NUVA): Free Stock Analysis
To read this article on Zacks.com click here.